Xarelto (rivaroxaban) was introduced to the market in July 2011 by Janssen Pharmaceuticals, a Johnson & Johnson (J&J) company. It is co-marketed by Bayer. The safety and effectiveness of Xarelto has been questioned because of the several complaints from patients. In fact, some of them have already filed lawsuits against the Xarelto manufacturer. For a more in depth discussion about this issue, affected patients may refer to http://www.xareltolawsuit.us.
On January 9, 2012, the Reuters reported that that Britain’s National Institute for Health and Clinical 0 (NICE) is asking Bayer to provide more safety data before it can recommend the drug for use in the state health services.
Xarelto is a prescription anticoagulant drug approved for the treatment of pulmonary embolism, deep vein thrombosis, and atrial fibrillation. It is also approved for patients undergoing knee or hip replacement surgery to prevent deep vein thrombosis and pulmonary embolism.
Experts say that Xarelto is a new drug and regulatory agencies have not yet collected sufficient data to decide whether the drug poses a major risk to consumers. The preliminary data suggest that there may be unrevealed risks associated with Xarelto. People who have suffered from the side effects of Xarelto may still be able to recover for their injuries, experts say.
Reports say that there are already a number of adverse events that have been included in the U.S. Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) regarding Xarelto.
Hemorrhage, or bleeding, is one of the most common negative side effects reported in FAERS with Xarelto as the primary suspect drug. Signs and symptoms of Xarelto-induced internal bleeding may vary, depending on the location of the bleeding, and what body functions are affected.
Other negative side effects linked with Xarelto as reported in the FAERS include thrombosis (blood clots); cerebrovascular accidents (an event that leads to a stroke, such as a cerebral hemorrhage); decreased hemoglobin (a substance that carries oxygen in red blood cells); ); peripheral edema (swelling of the lower limbs); hematoma (a semisolid mass in the bloodand dyspnea (difficulty breathing).
The FDA has announced that it is now in the process of evaluating the reported bleeding events in patients being treated with Xarelto to know if the risks outweigh the benefits of the drug.
References:
reuters.com/article/2014/06/14/us-bayer-suit-idUSKBN0EP0HW20140614
pharmatimes.com/Article/14-02-17/FDA_rejects_Bayer_J_J_s_Xarelto_again.aspx
medicaldaily.com/blood-thinner-xarelto-blamed-deaths-and-serious-injuries-lawsuit-276604
On January 9, 2012, the Reuters reported that that Britain’s National Institute for Health and Clinical 0 (NICE) is asking Bayer to provide more safety data before it can recommend the drug for use in the state health services.
Xarelto is a prescription anticoagulant drug approved for the treatment of pulmonary embolism, deep vein thrombosis, and atrial fibrillation. It is also approved for patients undergoing knee or hip replacement surgery to prevent deep vein thrombosis and pulmonary embolism.
Experts say that Xarelto is a new drug and regulatory agencies have not yet collected sufficient data to decide whether the drug poses a major risk to consumers. The preliminary data suggest that there may be unrevealed risks associated with Xarelto. People who have suffered from the side effects of Xarelto may still be able to recover for their injuries, experts say.
Reports say that there are already a number of adverse events that have been included in the U.S. Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) regarding Xarelto.
Hemorrhage, or bleeding, is one of the most common negative side effects reported in FAERS with Xarelto as the primary suspect drug. Signs and symptoms of Xarelto-induced internal bleeding may vary, depending on the location of the bleeding, and what body functions are affected.
Other negative side effects linked with Xarelto as reported in the FAERS include thrombosis (blood clots); cerebrovascular accidents (an event that leads to a stroke, such as a cerebral hemorrhage); decreased hemoglobin (a substance that carries oxygen in red blood cells); ); peripheral edema (swelling of the lower limbs); hematoma (a semisolid mass in the bloodand dyspnea (difficulty breathing).
The FDA has announced that it is now in the process of evaluating the reported bleeding events in patients being treated with Xarelto to know if the risks outweigh the benefits of the drug.
References:
reuters.com/article/2014/06/14/us-bayer-suit-idUSKBN0EP0HW20140614
pharmatimes.com/Article/14-02-17/FDA_rejects_Bayer_J_J_s_Xarelto_again.aspx
medicaldaily.com/blood-thinner-xarelto-blamed-deaths-and-serious-injuries-lawsuit-276604